I let these 2 videos speak for themselves. I recorded them “screen-to-video” and saved it before Vivek R. can make them “disappear” as he made his Soros connection “disappear” from Wikipedia (he paid someone to “sanitize” Wikipedia before he ran against DJT). The first video is more detailed, created by a financial adviser and Venture Capital manager who also completed series 7, 14, 24, 27, 63, 65 financial regulatory exams (he knows what he’s talking about!). The second video is a short version for those who don’t want to watch 15 minutes of great information in video 1 (I promise, your time is NOT wasted, when you chose to watch the more detailed video!)
This is proof that Vivek R ran a “pump and dump” scheme, making Millions while people lost all the money they invested over night!
And here is a graphic that shows how people lost their money. He & his family and friends dumped $2 billion of stock just before the medication failed (again). “He pumped up the image and the name so people invested, while he was selling out,” said Jeffrey Sonnenfeld, a scholar at the Yale School of Management who tracks Ramaswamy’s business dealings. “That’s classic ‘pump and dump.’”. Vivek R.’s own tax returns show he opportunely sold out of nearly $40 million of Roivant stock right as Axovant’s hype was peaking.
Btw., in 2020, Ramaswamy reduced his stake in Roivant Sciences, with his tax returns showing he made nearly $200 million in a sweet deal with Sumitomo right before the company’s valuation shrank fivefold after its SPAC-driven public listing. Meanwhile, Ramaswamy’s pharma companies are behaving like patent trolls, persistently suing both Pfizer and Moderna and weirdly claiming ownership of their mRNA COVID vaccines. Ramaswamy’s campaign claims that Ramaswamy has helped develop countless new drugs, but Roivant’s own SEC filings show the company has only ever commercialized one drug, the obscure skincare drug VTAMA.
More information I gathered from an article written by Jeffrey A. Sonnenfeld, Senior Associate Dean for Leadership Studies & Lester Crown Professor in the Practice of Management, who spent quit some time to debated Vivek R. and investigated and monitored him pretty closely
It is noteworthy that convicted “pharma bro” Martin Shkreli, who first came to prominence by jacking up the price of a life-saving 62-year-old drug frequently used by HIV and malaria patients by more than 5000% before going to prison for securities fraud, has called Ramaswamy “a friend” and one of his “biggest investors.”
Ramaswamy’s other business, Strive Asset Management, is even more of an illusion. Its assets under management have stagnated as the company is reduced to begging for consulting contracts from politicos in state governments, an obvious conflict of interest given Ramaswamy’s political activities. Strive has some of the highest fees of any of its peers and is now facing multiple lawsuits from former employees who say they were aggressively pressured into violating securities laws and that Ramaswamy routinely exaggerated his company’s abilities.
Interestingly while he attacks ESG hiring priorities in the name of meritocracy, he happily staffs his enterprise leadership ranks through cronyism (hiring his high-school pal as president of one firm) and nepotism (hiring his brother and mother to help lead another firm).
On a side note: While campaigning for the presidency, Vivek R. called himself a “scientist” and said, “I developed a number of medicines.” – What a pathological liar!!!